AEGiS-FDA: Viramume Warning Food and Drug AdministrationImportant note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
Click here to return to FDA main menu
DonateNow


Viramume Warning

Food and Drug Administration - January 28, 2004
Richard Klein, Kimberly Struble


Boehringer Ingelheim Pharmaceuticals recently issued a Dear Health Care Professional letter regarding clarification of risk factors for severe, life-threatening and fatal hepatotoxicity with VIRAMUNE (nevirapine). A copy of the letter and revised labeling can be found at www.viramune.com
040128
FD040102

SOURCE: Food and Drug Administration (FDA).

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, the Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .